SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-62918"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-62918" > 5alfa-reductase 2 p...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003503naa a2200433 4500
001oai:DiVA.org:uu-62918
003SwePub
008080118s2002 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:1941300
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-629182 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:19413002 URI
0247 a https://doi.org/10.1097/00008571-200206000-000062 DOI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Söderström, Torbjörnu Uppsala universitet,Institutionen för medicinska vetenskaper4 aut
2451 0a 5alfa-reductase 2 polymorphisms as risk factors in prostate cancer
264 1b Ovid Technologies (Wolters Kluwer Health),c 2002
338 a print2 rdacarrier
520 a Prostate cancer is a significant cause of death in Western countries and is under the strong influence of androgens. The steroid 5alpha-reductase 2 catalyzes the metabolism of testosterone into the more potent androgen dihydrotestosterone in the prostate gland. The enzyme is a target in pharmacological treatment of benign prostatic hyperplasia using specific inhibitors such as finasteride. Makridakis et al. have characterized the V89L and A49T polymorphisms in recombinant expression systems. The L allelic variant has a lower Vmax/Km ratio than the V variant. In the A49T polymorphism, the T variant has an increased Vmax/Km ratio. We performed a population-based case-control study of the impact of the SRD5A2 V89L and A49T polymorphisms on the risk of prostate cancer. We also studied the relation between the genotypes and age at diagnosis, tumor, node, metastasis stage, differentiation grade, prostate specific antigen and heredity. The study included 175 prostate cancer patients and 159 healthy controls that were matched for age. There was an association with SRD5A2 V89L LL genotype and metastases at the time of diagnosis, OR 5.67 (95% CI 1.44-22.30) when adjusted for age, differentiation grade, T-stage and prostate specific antigen. Heterozygous prostate cancer cases that carried the SRD5A2 A49T AT genotype were significantly younger than cases that carried the AA genotype, (mean age 66 years vs 71, P = 0.038). The SRD5A2 V89L and A49T polymorphisms were, however, not associated with altered prostate cancer risk. Further studies of the V89L polymorphism may lead to better understanding of the etiology of prostate cancer metastases.
653 a prostate cancer
653 a 5-[alpha] reductase 2
653 a polymorphism
653 a metastasis
653 a MEDICINE
653 a MEDICIN
7001 a Wadelius, Miau Uppsala universitet,Klinisk farmakogenomik och osteoporos4 aut0 (Swepub:uu)miawadel
7001 a Andersson, Swen-Olov4 aut
7001 a Johansson, Jan-Erik4 aut
7001 a Johansson, Sara4 aut
7001 a Granath, Fredriku Karolinska Institutet4 aut
7001 a Rane, Andersu Karolinska Institutet4 aut
7102 a Uppsala universitetb Institutionen för medicinska vetenskaper4 org
7730 t Pharmacogeneticsd : Ovid Technologies (Wolters Kluwer Health)g 12:4, s. 307-12q 12:4<307-12x 0960-314Xx 1473-561X
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-62918
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:1941300
8564 8u https://doi.org/10.1097/00008571-200206000-00006

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy